{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:16:48Z","timestamp":1760145408136,"version":"build-2065373602"},"reference-count":22,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>A 48-year-old woman without obvious environmental risk factors was diagnosed with metastatic urothelial carcinoma harboring a mutation in EGFR typical of driver mutations for non-small cell lung cancer. Within a year, her cancer progressed on four standard therapies for urothelial cancer, including cancer in lungs, liver, bone, and brain. As fifth-line therapy, she received osimertinib, leading to a complete response in the brain and improvement elsewhere, and the cancer remained controlled for six months. Targeted therapy for rare driver mutations can be effective in urothelial cancer and should be considered prior to exhausting standard therapies.<\/jats:p>","DOI":"10.3390\/curroncol31070298","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T15:05:51Z","timestamp":1721142351000},"page":"4015-4021","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1835-3782","authenticated-orcid":false,"given":"Sareen T.","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology Division, Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"VanderWeele","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology Division, Feinberg School of Medicine, Chicago, IL 60611, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/2326-6066.CIR-18-0758","article-title":"The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes","volume":"7","author":"Pfannstiel","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_2","unstructured":"American Cancer Society (2023). Cancer Facts and Figures 2023, American Cancer Society."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis","volume":"361","author":"Vale","year":"2003","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2023.41.6_suppl.439","article-title":"Enfortumab Vedotin with or without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","volume":"41","author":"Milowsky","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma","volume":"389","author":"Sonpavde","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering Precision Medicine through an International Consortium","volume":"7","author":"Consortium","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bednova, O., and Leyton, J.V. (2020). Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197268"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging strategies to overcome resistance to third-generation EGFR inhibitors","volume":"15","author":"Shi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_10","first-page":"1957","article-title":"Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder","volume":"7","author":"Chow","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"244ra291","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"Kundra","year":"2023","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1464-410X.2009.09101.x","article-title":"A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Clinical and pathological results","volume":"106","author":"Pruthi","year":"2010","journal-title":"BJU Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1002\/mco2.236","article-title":"Synergistic augmentation of osimertinib-induced autophagic death by proguanil or rapamycin in bladder cancer","volume":"4","author":"Xiao","year":"2023","journal-title":"MedComm"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102351","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Iyer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/298\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:16:32Z","timestamp":1760109392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,14]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["curroncol31070298"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31070298","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,7,14]]}}}